Building a future powered by mucus: Breakout Labs funds Inhalon Biopharma
Breakout Labs has recently funded our 46th company, Inhalon Biopharma. Inhalon Biopharma is a preclinical stage company that aims to harness “muco-trapping” monoclonal antibodies (mAb) for treating diseases of the respiratory tract. Their lead product is for treatment and prevention of respiratory syncytial virus (RSV). RSV infections affect over 2.5M children in the U.S. each year and are the leading cause of viral infection-related hospitalization in both children and elderly patients.
Inhalon’s technology enables efficient trapping of pathogens in mucus secretions, thereby preventing them from reaching target cells and facilitating their rapid elimination from the airways.
Inhalon was founded by Dr. Sam Lai and Dr. Thomas Moench and the technology was developed out of University of North Carolina — Chapel Hill and Johns Hopkins University. Inhalon’s senior management team has over 4 decades of product development experience in monoclonal antibodies, infectious disease and pulmonary drug delivery. Inhalon is based in Carrboro, NC.
